{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:56:47Z","timestamp":1792022207934,"version":"4.4.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T00:00:00Z","timestamp":1564704000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"SPANISH AIDS Research Network","award":["RD16\/0025\/0001"],"award-info":[{"award-number":["RD16\/0025\/0001"]}]},{"name":"SPANISH AIDS Research Network","award":["RD16\/0025\/0036"],"award-info":[{"award-number":["RD16\/0025\/0036"]}]},{"name":"SPANISH AIDS Research Network","award":["RD16CIII\/0002\/0006"],"award-info":[{"award-number":["RD16CIII\/0002\/0006"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.cmi.2017.11.016","type":"journal-article","created":{"date-parts":[[2017,11,26]],"date-time":"2017-11-26T23:15:16Z","timestamp":1511738116000},"page":"900-907","source":"Crossref","is-referenced-by-count":24,"title":["Impact of dolutegravir and efavirenz on immune recovery markers: results from a randomized clinical trial"],"prefix":"10.1016","volume":"24","author":[{"given":"J.R.","family":"Blanco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Alejos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2017.11.016_bib1","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1086\/510746","article-title":"CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression","volume":"44","author":"Moore","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2017.11.016_bib2","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/QAD.0000000000000545","article-title":"The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation","volume":"29","author":"Wada","year":"2015","journal-title":"AIDS"},{"key":"10.1016\/j.cmi.2017.11.016_bib3","first-page":"75","article-title":"For timing of HAART is less more? CD4+\/CD8+ ratio and CD4+ percentage as surrogate markers for more complex immunological features","volume":"37","author":"Fogli","year":"2014","journal-title":"New Microbiol"},{"key":"10.1016\/j.cmi.2017.11.016_bib4","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1056\/NEJM199001183220305","article-title":"The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1","volume":"322","author":"Fahey","year":"1990","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2017.11.016_bib5","doi-asserted-by":"crossref","first-page":"5737","DOI":"10.1182\/blood-2009-02-204172","article-title":"Hodgkin lymphoma in the swiss HIV cohort study","volume":"113","author":"Clifford","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2017.11.016_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0085798","article-title":"Increased risk of serious non\u2013AIDS-related events in HIV-infected subjects on antiretroviral therapy associated with a low CD4\/CD8 ratio","volume":"9","author":"Serrano-Villar","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2017.11.016_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004078","article-title":"HIV-infected individuals with low CD4\/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality","volume":"10","author":"Serrano-Villar","year":"2014","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.cmi.2017.11.016_bib8","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1016\/S2352-3018(15)00006-5","article-title":"CD4\/CD8 ratio normalisation and non\u2013AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study","volume":"2","author":"Mussini","year":"2015","journal-title":"Lancet HIV"},{"key":"10.1016\/j.cmi.2017.11.016_bib9","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1089\/aid.2015.0385","article-title":"The CD4\/CD8 ratio is inversely associated with carotid intima-media thickness progression in human immunodeficiency virus\u2013infected patients on antiretroviral treatment","volume":"32","author":"Bernal Morell","year":"2016","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.cmi.2017.11.016_bib10","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/hiv.12081","article-title":"The CD4:CD8 ratio is associated with markers of age-associated disease in virally suppressed HIV-infected patients with immunological recovery","volume":"15","author":"Serrano-Villar","year":"2014","journal-title":"HIV Med"},{"key":"10.1016\/j.cmi.2017.11.016_bib11","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/QAI.0000000000001013","article-title":"Enhanced normalization of CD4\/CD8 ratio with earlier antiretroviral therapy at primary HIV infection [brief report]","volume":"73","author":"Thornhill","year":"2016","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.cmi.2017.11.016_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0161594","article-title":"Low CD4\/CD8 ratio is associated with non AIDS-defining cancers in patients on antiretroviral therapy: ANRS CO8 (Aproco\/Copilote) prospective cohort study","volume":"11","author":"Hema","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2017.11.016_bib13","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1086\/432955","article-title":"CD4 lymphocyte percentage predicts disease progression in HIV-infected patients initiating highly active antiretroviral therapy with CD4 lymphocyte counts >350 lymphocytes\/mm\u00b3","volume":"192","author":"Hulgan","year":"2005","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2017.11.016_bib14","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1177\/135965350901400311","article-title":"CD4+ T-cell percentage is an independent predictor of clinical progression in AIDS-free antiretroviral-naive patients with CD4+ T-cell counts >200 cells\/mm\u00b3","volume":"14","author":"Guiguet","year":"2009","journal-title":"Antivir Ther"},{"key":"10.1016\/j.cmi.2017.11.016_bib15","first-page":"114","article-title":"CD4 percentage, CD4 number, and CD4:CD8 ratio in HIV infection: which to choose and how to use","volume":"2","author":"Taylor","year":"1989","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.cmi.2017.11.016_bib16","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1097\/QAD.0000000000001005","article-title":"CD4+\/CD8+ ratio, age, and risk of serious noncommunicable diseases in HIV-infected adults on antiretroviral therapy","volume":"30","author":"Castilho","year":"2016","journal-title":"AIDS"},{"key":"10.1016\/j.cmi.2017.11.016_bib17","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1469-0691.2011.03650.x","article-title":"Factors influencing the normalization of CD4+ T-cell count, percentage and CD4+\/CD8+ T-cell ratio in HIV-infected patients on long-term suppressive antiretroviral therapy","volume":"18","author":"Torti","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2017.11.016_bib18","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","article-title":"Dolutegravir plus abacavir\u2013lamivudine for the treatment of HIV-1 infection","volume":"369","author":"Walmsley","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2017.11.016_bib19","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/QAI.0000000000000790","article-title":"Dolutegravir plus abacavir\/lamivudine for the treatment of HIV-1 infection in antiretroviral therapy-naive patients: week 96 and week 144 results from the single randomized clinical trial [brief report]","volume":"70","author":"Walmsley","year":"2015","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.cmi.2017.11.016_bib20","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2307\/2530374","article-title":"The analysis of failure times in the presence of competing risks","volume":"34","author":"Prentice","year":"1978","journal-title":"Biometrics"},{"key":"10.1016\/j.cmi.2017.11.016_bib21","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A\u00a0proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J\u00a0Am Stat Assoc"},{"key":"10.1016\/j.cmi.2017.11.016_bib22","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1002\/sim.2712","article-title":"Tutorial in biostatistics: competing risks and multi-state models","volume":"26","author":"Putter","year":"2007","journal-title":"Stat Med"},{"key":"10.1016\/j.cmi.2017.11.016_bib23","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/0531-5565(94)90036-1","article-title":"Age-related changes in immune parameters in a very old population of Swedish people: a longitudinal study","volume":"29","author":"Wikby","year":"1994","journal-title":"Exp Gerontol"},{"key":"10.1016\/j.cmi.2017.11.016_bib24","doi-asserted-by":"crossref","first-page":"B378","DOI":"10.1093\/gerona\/50A.6.B378","article-title":"Immune parameters in a longitudinal study of a very old population of Swedish people: a comparison between survivors and nonsurvivors","volume":"50","author":"Ferguson","year":"1995","journal-title":"J\u00a0Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.cmi.2017.11.016_bib25","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0047-6374(97)00151-6","article-title":"Changes in CD8 and CD4 lymphocyte subsets, T cell proliferation responses and non-survival in the very old: the Swedish longitudinal octo-immune study","volume":"102","author":"Wikby","year":"1998","journal-title":"Mech Ageing Dev"},{"key":"10.1016\/j.cmi.2017.11.016_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0077665","article-title":"Predictors of CD4:CD8 ratio normalization and its effect on health outcomes in the era of combination antiretroviral therapy","volume":"8","author":"Leung","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2017.11.016_bib27","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/COH.0000000000000086","article-title":"CD8 T cell persistence in treated HIV infection","volume":"9","author":"Mudd","year":"2014","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.cmi.2017.11.016_bib28","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/QAI.0000000000000286","article-title":"Factors associated with CD8+ T-cell activation in HIV-1\u2013infected patients on long-term antiretroviral therapy","volume":"67","author":"Zheng","year":"2014","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.cmi.2017.11.016_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0165774","article-title":"CMV+ serostatus associates negatively with CD4:CD8 ratio normalization in controlled HIV-infected patients on cART","volume":"11","author":"Poizot-Martin","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2017.11.016_bib30","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1089\/aid.2014.0080","article-title":"Chronic inflammation in a long-term cohort of HIV-infected patients according to the normalization of the CD4:CD8 ratio","volume":"30","author":"Saracino","year":"2014","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.cmi.2017.11.016_bib31","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1097\/QAD.0000000000001181","article-title":"Differential CD4+ cell count increase and CD4+:CD8+ ratio normalization with maraviroc compared with tenofovir","volume":"30","author":"Chan","year":"2016","journal-title":"AIDS"},{"key":"10.1016\/j.cmi.2017.11.016_bib32","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1016\/j.jaci.2015.05.047","article-title":"Host, disease, and antiretroviral factors are associated with normalization of the CD4:CD8 ratio after initiating antiretroviral therapy","volume":"136","author":"Winston","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.cmi.2017.11.016_bib33","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000003108","article-title":"Comparative impact of suppressive antiretroviral regimens on the CD4\/CD8 T-cell ratio: a cohort study","volume":"95","author":"Masi\u00e1","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.cmi.2017.11.016_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140519","article-title":"Antiretroviral regimens and CD4\/CD8 ratio normalization in HIV-infected patients during the initial year of treatment: a cohort study","volume":"10","author":"De Salvador-Guillou\u00ebt","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2017.11.016_bib35","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.3851\/IMP2350","article-title":"A\u00a0pilot study to assess inflammatory biomarker changes when raltegravir is added to a virologically suppressive HAART regimen in HIV-1\u2013infected patients with limited immunological responses","volume":"17","author":"Lichtenstein","year":"2012","journal-title":"Antivir Ther"},{"key":"10.1016\/j.cmi.2017.11.016_bib36","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/jac\/dkt406","article-title":"Dual therapy with etravirine plus raltegravir for virologically suppressed HIV-infected patients: a pilot study","volume":"69","author":"Monteiro","year":"2014","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2017.11.016_bib37","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/jac\/dkw375","article-title":"Different impact of raltegravir versus efavirenz on CD4\/CD8 ratio recovery in HIV-infected patients","volume":"72","author":"Serrano-Villar","year":"2017","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2017.11.016_bib38","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1093\/cid\/ciw076","article-title":"Determinants of a low CD4\/CD8 ratio in HIV-1\u2013infected individuals despite long-term viral suppression","volume":"62","author":"Caby","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2017.11.016_bib39","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1080\/15284336.2016.1189754","article-title":"Characteristics associated with virologic failure in high-risk HIV-positive participants with prior failure: a post hoc analysis of ACTG 5251","volume":"17","author":"Robbins","year":"2016","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.cmi.2017.11.016_bib40","doi-asserted-by":"crossref","first-page":"e449","DOI":"10.1016\/S2352-3018(17)30110-8","article-title":"Efficacy of oral pre-exposure prophylaxis (PrEP) for HIV among women with abnormal vaginal microbiota: a post-hoc analysis of the randomised, placebo-controlled partners PrEP study","volume":"4","author":"Heffron","year":"2017","journal-title":"Lancet HIV"},{"key":"10.1016\/j.cmi.2017.11.016_bib41","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/ACI.0b013e3283609831","article-title":"Post-hoc data analysis: benefits and limitations","volume":"13","author":"Curran-Everett","year":"2013","journal-title":"Curr Opin Allergy Clin Immunol"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X1730647X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X1730647X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T18:47:28Z","timestamp":1659984448000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X1730647X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S1198743X1730647X"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2017.11.016","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]}}}